Search details
1.
Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells.
J Immunol
; 198(2): 729-740, 2017 01 15.
Article
in English
| MEDLINE | ID: mdl-27927966
2.
Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms.
PLoS One
; 15(11): e0242092, 2020.
Article
in English
| MEDLINE | ID: mdl-33206686
3.
Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?
Front Immunol
; 10: 79, 2019.
Article
in English
| MEDLINE | ID: mdl-30804929
4.
T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
Autoimmunity
; 49(8): 523-531, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27560779
5.
NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment.
Oncotarget
; 6(16): 14123-38, 2015 Jun 10.
Article
in English
| MEDLINE | ID: mdl-26053099
6.
Pepsin digest of wheat gliadin fraction increases production of IL-1ß via TLR4/MyD88/TRIF/MAPK/NF-κB signaling pathway and an NLRP3 inflammasome activation.
PLoS One
; 8(4): e62426, 2013.
Article
in English
| MEDLINE | ID: mdl-23658628
Results
1 -
6
de 6
1
Next >
>>